<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Elivaldogene autotemcel: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Elivaldogene autotemcel: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Elivaldogene autotemcel: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="139641" href="/d/html/139641.html" rel="external">see "Elivaldogene autotemcel: Drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F57216208"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hematologic malignancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hematologic malignancy, including life-threatening cases of myelodysplastic syndrome, has occurred in patients treated with elivaldogene autotemcel. Patients have been diagnosed between 14 months and 7.5 years after elivaldogene autotemcel administration, and the cancers appear to be the result of the elivaldogene autotemcel lentiviral vector, Lenti-D, integration in proto-oncogenes. Monitor patients closely for evidence of malignancy through complete blood counts at least every 6 months and through assessments for evidence for clonal expansion or predominance at least twice in the first year and annually thereafter; consider bone marrow evaluations as clinically indicated.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57878255"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Skysona</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F57226833"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Cellular Immunotherapy, Autologous</span>;</li>
<li>
<span class="list-set-name">Gene Therapy, Autologous</span></li></ul></div>
<div class="block dop drugH1Div" id="F57236121"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> A treatment course consists of multiple phases: 1) mobilization and apheresis to collect CD34+ cells for manufacturing, 2) myeloablative and lymphodepleting conditioning, and 3) elivaldogene autotemcel infusion, with a minimum of 48 hours washout between conditioning and elivaldogene autotemcel infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>For autologous use only; confirm patient identity matches unique patient identifiers on the cassette and infusion bag(s). </b>Elivaldogene autotemcel is provided as a single dose for infusion containing a suspension of CD34+ cells in 1 or more infusion bags; confirm correct number of infusion bags are present (see lot information sheet).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Mobilization: </i></b>Confirm a negative HIV test prior to beginning mobilization and apheresis of CD34+ cells if antiretrovirals are required for HIV prophylaxis. Patients should not take prophylactic HIV antiretroviral medications for at least 1 month prior to mobilization (or for the expected duration for elimination of the medications) and until all cycles of apheresis are completed.</p>
<p style="text-indent:-2em;margin-left:6em;">Granulocyte colony-stimulating factor (G-CSF) and plerixafor were used for mobilization in clinical trials. The target collection is ≥12 × 10<sup>6</sup> CD34+ cells/kg. A back-up collection of CD34+ cells (either via apheresis or marrow harvest; refer to product labeling for details) is required for rescue treatment (if needed); collect and cryopreserve prior to myeloablative conditioning.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Myeloablative and lymphodepleting conditioning preparation:</i></b> Full myeloablative and lymphodepleting conditioning must be administered before infusion; in clinical trials, busulfan and cyclophosphamide/fludarabine, respectively, were used. Confirm availability of autologous elivaldogene autotemcel at the infusion center (and availability of back-up collection) prior to initiating myeloablative therapy. Refer to manufacturer's labeling for conditioning agents and specific protocols.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="52a7e5ad-2ceb-4d34-ba99-2571afadc0b5">Cerebral adrenoleukodystrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cerebral adrenoleukodystrophy:</b> Males: Children ≥4 years and Adolescents &lt;18 years: IV: Dose calculated based on patient weight prior to first apheresis and is specific to lot; see lot information sheet provided with product. Minimum recommended dose: 5 × 10<sup>6</sup> CD34+ cells/kg; administer after a washout period of at least 48 hours after completion of conditioning (refer to specific protocols).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F57236122"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; has not been studied in patients with kidney impairment.</p></div>
<div class="block dohp drugH1Div" id="F57236123"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; has not been studied in patients with hepatic impairment.</p></div>
<div class="block adr drugH1Div" id="F57241446"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for children and adolescents; 48-hours post-administration of conditioning agents. Adverse reactions were more commonly reported in the first 60-days after elivaldogene autotemcel treatment and may be attributed to conditioning agents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, pruritus, skin hyperpigmentation, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, constipation, decreased appetite, diarrhea, nausea, stomatitis (including colitis, gastrointestinal inflammation, and proctitis), vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, febrile neutropenia, leukopenia, lymphocytopenia, neutropenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Transfusion reaction (including anaphylaxis and hypersensitivity reactions)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (including bacterial infection and viral infection; opportunistic infection [including atypical mycobacterial infection, BK virus infection, candidiasis, cytomegalovirus disease, human herpes virus-6 viremia, pseudomonas infection, reactivation of latent Epstein-Barr virus]; severe infection [including bacteremia, transverse myelitis])</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (including akathisia and agitation), headache, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis, oropharyngeal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Myelodysplastic syndrome, pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hematologic malignancy</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction</p></div>
<div class="block coi drugH1Div" id="F57216210"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F57261757"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cytopenias: Prolonged (&gt;1 year) cytopenias including pancytopenia may occur following lymphodepleting chemotherapy and elivaldogene autotemcel infusion. Unresolved (by day 100 following elivaldogene autotemcel treatment) grade 3 and 4 cytopenias included lymphocytopenia, neutropenia, and thrombocytopenia. Two patients required blood and platelet transfusion as well as growth factor therapy (G-CSF for up to 6 months and eltrombopag for up to 14 months) following elivaldogene autotemcel treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic malignancy: May cause hematologic malignancies; consider hematologist consult and alternative therapies prior to initiating.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Allergic reactions may occur with elivaldogene autotemcel. Serious hypersensitivity reactions, including anaphylaxis, may be due to the dimethyl sulfoxide (DMSO) component.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Serious infections (including life-threatening or fatal infections) occurred in patients after elivaldogene autotemcel infusion, including ≥ grade 3 infections. Viral, bacterial, and unspecified infections were reported. Neutropenic fever has been observed within 2 weeks after elivaldogene autotemcel infusion. Opportunistic infections reported within the first 3 months include BK cystitis, cytomegalovirus reactivation, human herpes virus-6 viremia, candidiasis, and bacteremias. After the first 3 months, opportunistic infections included atypical mycobacterium vascular device infection, pseudomonas bacteremia, and Epstein-Barr virus reactivations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neutrophil engraftment failure: There is a potential risk of neutrophil engraftment failure after treatment with elivaldogene autotemcel. Neutrophil engraftment failure is defined as failure to achieve 3 consecutive ANCs ≥500/mm<sup>3</sup> obtained on different days by day 43 after elivaldogene autotemcel infusion. If neutrophil engraftment failure occurs in a patient treated with elivaldogene autotemcel, provide rescue treatment with the backup collection of CD34+ cells.</p>
<p style="text-indent:-2em;margin-left:4em;">• Platelet engraftment delay: Delayed platelet engraftment has been observed with elivaldogene autotemcel treatment. Bleeding risk is increased prior to platelet engraftment and may continue after engraftment in patients with prolonged thrombocytopenia. Grade 3 thrombocytopenia has been observed on or after day 60. Patients should be made aware of the risk of bleeding until platelet recovery has been achieved.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during elivaldogene autotemcel treatment, and until immune recovery following treatment. The safety of immunization with live viral vaccines during or following elivaldogene autotemcel treatment has not been studied.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with HIV: Elivaldogene autotemcel has not been studied in patients with HIV-1, HIV-2, human T-lymphotropic virus 1 (HTLV-1), or HTLV-2. A negative serology test for HIV is necessary to ensure acceptance of apheresis material to manufacture elivaldogene autotemcel. Apheresis material from patients with a positive HIV test will not be accepted for elivaldogene autotemcel manufacturing. Antiretroviral medications are not recommended within 1 month prior to mobilization or the expected duration for elimination, and until all cycles of apheresis are completed; may interfere with manufacturing of the apheresed cells. Delay mobilization and apheresis of CD34+ cells in patients requiring antiretroviral prophylaxis until HIV infection is ruled out.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Dimethyl sulfoxide: Elivaldogene autotemcel contains DMSO, which is associated with serious hypersensitivity reactions, including anaphylaxis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Universal precautions: Elivaldogene autotemcel contains human blood cells that are genetically modified with replication-incompetent, self-inactivating Lenti-D lentiviral vector; follow universal precautions and facility biosafety guidelines for handling and disposal to avoid potential transmission of infectious diseases.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: After elivaldogene autotemcel administration, the standard procedures for patient management after hematopoietic cell transplantation should be followed. Irradiate any blood products required within the first 3 months after elivaldogene autotemcel infusion. Patients should not donate blood, organs, tissues, or cells at any time in the future.</p></div>
<div class="block dosfc drugH1Div" id="F57875346"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;">Skysona is composed of one or two infusion bags which contain 4 to 30 × 10<sup>6</sup> cells/mL suspended in cryopreservation solution. Each infusion bag contains ~20 mL. A single dose of Skysona contains a minimum of 5 × 10<sup>6</sup> CD34+ cells/kg suspended in cryopreservation solution.</p></div>
<div class="block foc drugH1Div" id="F57878256"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Skysona:  (1 ea)</p></div>
<div class="block geq drugH1Div" id="F57878254"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block admp drugH1Div" id="F57236125"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: For autologous use only; confirm patient identity matches unique patient identifiers on the cassette and infusion bag(s). </b>Elivaldogene autotemcel is provided as a single dose for infusion containing a suspension of CD34+ cells in 1 or more infusion bags; confirm correct number of infusion bags are present (see lot information sheet).</p>
<p style="text-indent:-2em;margin-left:2em;">IV: For IV use only. Prime tubing set with NS prior to infusion. Infuse each bag via gravity flow drip over &lt;60 minutes. Do not use an inline blood filter or an infusion pump. After infusing each bag, flush all elivaldogene autotemcel remaining in infusion bag and any associated tubing with at least 50 mL NS to ensure that as many cells as possible are infused.</p>
<p style="text-indent:-2em;margin-left:2em;">Coordinate the timing of administration with thawing. If more than 1 bag is required, administer each infusion bag completely before proceeding to thaw and infuse the next bag. Infuse as soon as possible after thawing; must be administered within 4 hours after thawing.</p></div>
<div class="block sts drugH1Div" id="F57261760"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Keep the infusion bag(s) in the metal cassette(s) and store/transfer in the vapor phase of liquid nitrogen at ≤−140°C (≤−220°F) until ready for thaw and administration. Thaw prior to infusion. Do not refreeze after thawing. Do not irradiate, as this could lead to inactivation. Product must be administered within 4 hours after thawing. Contact manufacturer (1-833-999-6378) with any concerns about product or packaging upon receipt.</p></div>
<div class="block usep drugH1Div" id="F57226834"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">To slow the progression of neurologic dysfunction in males with early, active cerebral adrenoleukodystrophy (CALD) (FDA approved in ages 4 to 17 years). <b>Note: </b>Early, active CALD refers to asymptomatic or mildly symptomatic disease with neurologic function score ≤1, gadolinium enhancement on MRI, and Loes score of 0.5 to 9.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use:</p>
<p style="text-indent:-2em;margin-left:6em;">Has not been studied in patients with CALD secondary to head trauma and does not prevent the development of or treat adrenal insufficiency due to adrenoleukodystrophy.</p>
<p style="text-indent:-2em;margin-left:6em;">An immune response to elivaldogene autotemcel may limit the persistence of descendent cells of elivaldogene autotemcel, causing rapid loss of efficacy of elivaldogene autotemcel in patients with full deletion of the human adenosine triphosphate binding cassette, sub family D, member 1 transgene.</p></div>
<div class="block mst drugH1Div" id="F57261747"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Elivaldogene autotemcel may be confused with axicabtagene ciloleucel, betibeglogene autotemcel, brexucabtagene autoleucel, ciltacabtagene autoleucel, idecabtagene vicleucel, lisocabtagene maraleucel, sipuleucel-T, tisagenlecleucel.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F57277400"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F57277397"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiretroviral Agents: May diminish the therapeutic effect of Elivaldogene Autotemcel. Management: Avoid use of antiretroviral medications for at least one month, or for the amount of time required for elimination of the retroviral medication, prior to stem cell mobilization and until the all apheresis cycles are finished<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines: Elivaldogene Autotemcel may enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines.  Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F57261748"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who could become pregnant and patients who could father a child should use effective contraception prior to beginning mobilization through at least 6 months after administration of elivaldogene autotemcel. Effective methods of contraception include an IUD or a combination hormonal contraceptive plus barrier contraception.</p>
<p style="text-indent:0em;margin-top:2em;">Also consider risks associated with myeloablative conditioning agents, including effects on fertility and the option to cryopreserve semen prior to therapy if appropriate.</p></div>
<div class="block pri drugH1Div" id="F57261749"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Reproduction studies have not been conducted. Consider risks associated with myeloablative conditioning agents.</p></div>
<div class="block mopp drugH1Div" id="F57236126"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Screen for hepatitis B virus, hepatitis C virus, human T-lymphotrophic virus 1 and 2, and HIV (1 and 2) prior to collection of cells for manufacturing. Confirm a negative HIV test prior to beginning mobilization and apheresis of CD34+ cells if antiretrovirals are required for HIV prophylaxis. Assess renal function (including CrCl) and hepatic function prior to treatment (to ensure appropriate for stem cell transplant therapy). Monitor neutrophil counts until engraftment has been achieved. Monitor platelet counts frequently until platelet engraftment and platelet recovery are achieved; perform CBC and other appropriate testing whenever clinical symptoms suggestive of bleeding arise. Monitor for signs/symptoms of hypersensitivity, infection, and/or bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor lifelong for hematologic malignancies, with a CBC (with differential) every 6 months for at least 15 years after elivaldogene autotemcel treatment; perform integration site analysis (or other testing) at months 6 and 12, and then annually. If a malignancy occurs, contact the manufacturer for instructions on sample collection for testing.</p></div>
<div class="block pha drugH1Div" id="F57261761"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Elivaldogene autotemcel is a gene therapy consisting of autologous CD34+ hematopoietic cells transduced with the Lenti-D lentiviral vector to add functional copies of the ABCD1 cDNA into the hematopoietic stem cells. After elivaldogene autotemcel infusion, transduced CD34+ hematopoietic stem cells engraft in the bone marrow and differentiate to produce various cell types, including monocytes (CD14+) capable of producing functional ALDP. Functional ALDP participates in the local degradation of very long chain fatty acids, which slows or possibly prevents further demyelination and inflammation.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Skysona.2022.09">
<a name="Skysona.2022.09"></a>Skysona (elivaldogene autotemcel) [prescribing information]. Somerville, MA: Bluebird Bio Inc; September 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 139669 Version 14.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
